These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7771503)

  • 1. Case report: diabetic ketoacidosis in a patient with glucagonoma.
    Anthony LB; Sharp SC; May ME
    Am J Med Sci; 1995 Jun; 309(6):326-7. PubMed ID: 7771503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update.
    Fenkci SM; Fidan Yaylali G; Sermez Y; Akdam H; Sabir N; Kiraç S
    Endocr Relat Cancer; 2005 Jun; 12(2):449-54. PubMed ID: 15947115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glucagonoma with diabetic ketoacidosis; case report].
    Lefebvre J; Lelièvre G; Dalle-Furnari MA; Proye C; Mazzuca M; Garraud JC; Luyckx A; Linquette M
    Diabete Metab; 1982 Sep; 8(3):191-5. PubMed ID: 6292011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Malignant glucagonoma: an uncommon cause of new onset diabetes].
    Guerrero Vázquez R; Oliva Rodríguez R; Cuenca Cuenca JI; Sánchez Alberdi F; Navarro González E
    Endocrinol Nutr; 2011 Apr; 58(4):199-201. PubMed ID: 21334267
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversal of a neurologic paraneoplastic syndrome with octreotide (Sandostatin) in a patient with glucagonoma.
    Holmes A; Kilpatrick C; Proietto J; Green MD
    Am J Med; 1991 Oct; 91(4):434-6. PubMed ID: 1951389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
    Moattari AR; Cho K; Vinik AI
    Surgery; 1990 Sep; 108(3):581-7. PubMed ID: 2168587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glucagonoma syndrome in a multihormonal pancreatic tumor].
    Keller U; Fankhauser S; Schumacher A; Trimble ER; Heitz PU
    Schweiz Med Wochenschr; 1982 Feb; 112(9):297-304. PubMed ID: 6281878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
    Bouin M; Aoust LD
    Gastroenterol Clin Biol; 2002 Oct; 26(10):926-9. PubMed ID: 12434103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A particularly aggressive combined glucagonoma and gastrinoma syndrome.
    Balian A; Fromont C; Naveau S; Bonte E; Belloula D; Giraud V; Montembault S; Capron F; Chaput JC
    Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1417-9. PubMed ID: 10654804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagonoma syndrome with increased lactate dehydrogenase isoenzymes: octreotide treatment.
    Siller GM; Strutton GM; Moore GA; Kanowski DM; Nedwich JA
    Australas J Dermatol; 1994; 35(1):11-4. PubMed ID: 7528001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagonoma syndrome: diagnosis and treatment.
    Zeng J; Wang B; Ma D; Li F
    J Am Acad Dermatol; 2003 Feb; 48(2):297-8. PubMed ID: 12582409
    [No Abstract]   [Full Text] [Related]  

  • 12. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.
    Rosenbaum A; Flourie B; Chagnon S; Blery M; Modigliani R
    Digestion; 1989; 42(2):116-20. PubMed ID: 2548911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.
    Jockenhövel F; Lederbogen S; Olbricht T; Schmidt-Gayk H; Krenning EP; Lamberts SW; Reinwein D
    Clin Investig; 1994 Jan; 72(2):127-33. PubMed ID: 8186658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.
    Kimbara S; Fujiwara Y; Toyoda M; Chayahara N; Imamura Y; Kiyota N; Mukohara T; Fukunaga A; Oka M; Nishigori C; Minami H
    Clin J Gastroenterol; 2014 Jun; 7(3):255-9. PubMed ID: 26183746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-secreting pancreatic islet cell carcinoma, containing insulin and somatostatin, with hypoglycemic attack.
    Yano T; Yamamoto N; Fujimori K; Inamori S; Hayashi H; Mizumoto R
    Am J Gastroenterol; 1982 Jun; 77(6):387-91. PubMed ID: 6124121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections.
    Lo CH; Ho CL; Shih YL
    QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434
    [No Abstract]   [Full Text] [Related]  

  • 17. Rare presentation of endocrine pancreatic tumour: a case of glucagonoma without necrolytic migratory erythema?
    Manes G; Pellegrini A; Riccardi F; Uomo G
    Ital J Gastroenterol; 1995 Jun; 27(5):248-9. PubMed ID: 8541575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration.
    Santangelo WC; Unger RH; Orci L; Dueno MI; Popma JJ; Krejs GJ
    Pancreas; 1986; 1(5):464-9. PubMed ID: 2882503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma-syndrome.
    Schmid R; Allescher HD; Schepp W; Hölscher A; Siewert R; Schusdziarra V; Classen M
    Hepatogastroenterology; 1988 Feb; 35(1):34-7. PubMed ID: 2896149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogue and tissue cultures in the study of a human malignant glucagonoma.
    Ahlman H; Ahlund L; Dahlström A; Grimelius L; Theodorsson E
    J Surg Oncol; 1990 Jul; 44(3):191-9. PubMed ID: 2164620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.